Neuroprotective action of MPEP, a selective mGluR5 antagonist, in methamphetamine-induced dopaminergic neurotoxicity

K Gołembiowska1, J Konieczny, S Wolfarth

  • 1Department of Pharmacology, Institute of Pharmacology, Polish Academy of Sciences, 12 Smetna Street, 31-343 Cracow, Poland.

Neuropharmacology
|August 9, 2003
PubMed

Insights

The metabotropic glutamate receptor 5 (mGluR5) antagonist MPEP protected rat dopaminergic neurons from methamphetamine toxicity. MPEP reduced methamphetamine-induced dopamine release and hyperthermia, suggesting a neuroprotective role.

Area of Science:

  • Neuroscience
  • Pharmacology

Background:

  • Methamphetamine (METH) causes neurotoxicity to dopaminergic neurons.
  • Metabotropic glutamate receptor 5 (mGluR5) is implicated in neuronal function and drug effects.

Purpose of the Study:

  • To investigate the role of mGluR5 in methamphetamine-induced dopaminergic neurotoxicity in rats.
  • To evaluate the neuroprotective potential of an mGluR5 antagonist against methamphetamine effects.

Main Methods:

  • Rats received repeated methamphetamine injections, and striatal dopamine/metabolite levels were measured.
  • An mGluR5 antagonist, MPEP, was administered before methamphetamine to assess its effects.
  • Extracellular dopamine levels, dopamine release, and body temperature were monitored following MPEP administration.

Main Results:

  • Methamphetamine reduced striatal dopamine and metabolite levels.
  • MPEP administration reversed methamphetamine-induced dopamine depletion.
  • MPEP reduced methamphetamine-stimulated dopamine release and hyperthermia, but high intrastriatal MPEP increased dopamine.

Conclusions:

  • Blockade of mGluR5 by MPEP demonstrates neuroprotective effects against methamphetamine toxicity in dopaminergic neurons.
  • MPEP's neuroprotection may involve reducing METH-induced dopamine efflux and hyperthermia.
  • Targeting mGluR5 offers a potential therapeutic strategy for methamphetamine-induced neurotoxicity.

Related Concept Videos

Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Anticholinesterase Agents: Poisoning and Treatment01:26

Anticholinesterase Agents: Poisoning and Treatment

Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.     
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is slower than the...
Drugs Affecting Neurotransmitter Release or Uptake01:21

Drugs Affecting Neurotransmitter Release or Uptake

Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Adrenergic Agonists: Indirect-Acting Agents01:25

Adrenergic Agonists: Indirect-Acting Agents

Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...